PLX PAD

Drug Profile

PLX PAD

Alternative Names: Allogeneic ex-vivo expanded placental adherent stromal cells; Allogeneic mesenchymal-like adherent stromal cells; PLacental eXpanded cells; PLX-PAD cell therapy

Latest Information Update: 12 Jul 2017

Price : $50

At a glance

  • Originator Pluristem Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell differentiation modulators; Cell replacements; Dendritic cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia; Thromboangiitis obliterans
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Peripheral arterial disorders
  • Phase II Intermittent claudication; Muscle injury
  • Phase I Pulmonary arterial hypertension
  • Preclinical Duchenne muscular dystrophy; Ischaemic heart disorders; Preeclampsia; Tendon injuries

Most Recent Events

  • 10 Jul 2017 Phase-III clinical trials in Peripheral arterial disorders (In adults, In the elderly) in United Kingdom and USA before July 2017 (IM) (NCT03006770)
  • 10 Jul 2017 Austrian Agency for Health and Food Safety (AGES) clears a phase III trial in Critical limb ischaemia
  • 22 May 2017 Phase-III clinical trials in Peripheral arterial disorders (In adults, In the elderly) in Germany (IM) (NCT03006770)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top